CIML-NK Cells

also known as Cytokine-Induced Memory-like Natural Killer Cells · Cytokine-Induced Memory-Like NK cells · CIML NK

Developed for: acute myeloid leukemia · myelodysplastic syndrome · head and neck squamous cell carcinoma · metastatic melanoma · neuroblastoma · plasma cell myeloma · ovarian carcinoma
Investigated by: Dana-Farber Cancer Institute · Washington University School of Medicine · Children's Hospital Medical Center, Cincinnati · Altor BioScience · Biohaven Pharmaceuticals, Inc. · Bristol-Myers Squibb
+4 more
· Melanoma Research Alliance · Miltenyi Biomedicine GmbH · Rising Tide Foundation · Wugen, Inc.

Trials 10 · a red edge is where a trial was stopped

today NCT07635056 · Ph 2 NCT05629546 · Ph 1 NCT06321484 · Ph 1 NCT06152809 · Ph 1 NCT06138587 · Ph 1 NCT04354025 · Ph 2 NCT05580601 · Ph 1/2 NCT04893915 · Ph 2 NCT04634435 · Ph 1 NCT04290546 · Ph 1

20212022202320242025202620272028202920302031

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT05629546	Nov 2024 → Feb 2029 expected	metastatic melanoma	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1	NCT06321484	Oct 2024 → Nov 2026 expected	ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, refractory malignant neoplasm	Dana-Farber Cancer Institute	Recruiting	No outcome recorded
Phase 1	NCT06152809	Feb 2024 → Nov 2026 expected	acute myeloid leukemia	Dana-Farber Cancer Institute	Recruiting	No outcome recorded
Phase 1	NCT06138587	Jan 2024 → Feb 2027 expected	acute myeloid leukemia, myelodysplastic syndrome	Dana-Farber Cancer Institute	Recruiting	No outcome recorded
Phase 1	NCT04634435	Oct 2021 → Jan 2025	plasma cell myeloma	Biohaven Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04290546	Jul 2020 → Sep 2024	head and neck squamous cell carcinoma	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT05580601	May 2023 → Jan 2027 expected	acute myeloid leukemia	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 23 trials
Phase 2	NCT07635056	Jul 2026 → Jun 2031 expected	neuroblastoma	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 2	NCT04354025	Jun 2023 → Sep 2026	acute myeloid leukemia	Washington University School of Medicine	Withdrawn	No outcome recorded
Phase 2	NCT04893915	Jun 2022 → Dec 2024	acute myeloid leukemia, myelodysplastic syndrome	Washington University School of Medicine	Withdrawn	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

Field	Value	Cited text
Known as	CIML-NK Cells	“CIML NK cells are an allogeneic cell product derived from qualified donor natural killer (NK) cells” NCT04290546 ↗ 3 “Single dose infusion of BHV-1100 plus CIML NK Cells plus IVIG, followed by low dose IL-2” NCT04634435 ↗ NCT05580601 ↗ NCT07635056 ↗
Known as	CIML NK	“CIML NK (cellular therapy)” NCT06321484 ↗
Known as	Cytokine-Induced Memory-like Natural Killer Cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06152809 ↗ 3 NCT06138587 ↗ NCT06321484 ↗ NCT05629546 ↗
Known as	Cytokine-Induced Memory-Like NK cells	“* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)” NCT05580601 ↗ 2 NCT04354025 ↗ NCT04893915 ↗
Modality	Cell therapy	“CIML NK cells are an allogeneic cell product derived from qualified donor natural killer (NK) cells” NCT04290546 ↗
Route	Other	“CIML NK cell Infusion” NCT04290546 ↗